Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
PERGONAL is a gonadotropin combination therapy containing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) derived from human menopausal urine. It is primarily indicated for ovulation induction in infertility treatment and for stimulation of spermatogenesis in hypogonadal men. The drug works by directly stimulating the gonads to produce sex hormones and gametes.
As a product approaching loss of exclusivity with moderate competitive pressure (30/100), brand teams face significant revenue defense challenges and should expect reduced headcount in upcoming years.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
PERGONAL currently shows zero linked job openings, reflecting its mature, legacy status in a declining-growth therapeutic class. Professionals assigned to this product should expect a defensive, efficiency-focused commercial posture with limited career growth opportunities relative to newer assets.
Worked on PERGONAL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.